Practical Radiation Oncology最新文献

Background and purpose: We aimed to determine if ultra-hypofractionated radiotherapy (UHYPO-RT) delivering 6Gy x 5 fractions yields similar tumour necrosis compared to conventional radiotherapy (CONV-RT) with 2Gy x 25 fractions in soft tissue sarcoma (STS). The clinical significance of tumor necrosis on loco-regional recurrence-free survival (LRFS), distant disease-free survival (DDFS), and overall survival (OS) were assessed.

Materials and methods: Patients with localised STS treated with CONV-RT or UHYPO-RT followed by surgery were included. Good response was defined as tumour necrosis ≥ 90%, and poor response as < 90%. Mann-Whitney U-test compared median tumour necrosis. Chi-squared analysis was used for categorical variables. Kaplan-Meier function estimated LRFS, DDFS, and OS.

Results: A total of 64 patients received CONV-RT, and 45 received UHYPO-RT. The median tumour size was 7.0 cm, with the lower extremity being the most common site (55%). Myxofibrosarcoma (39%) and undifferentiated pleomorphic sarcoma (16%) were the most frequent histologies. The median time from radiotherapy to surgery was 35 days. There was a significant difference in median tumour necrosis between CONV-RT and UHYPO-RT, with rates of 40% and 60%, respectively (p = 0.022). Patients receiving UHYPO-RT had a higher percentage of tumour necrosis at the 90% cutoff, achieving 27% compared to 6% for CONV-RT (p = 0.003). In a median follow-up of 32 months, 12 patients (9%) experienced loco-regional recurrence, 24 patients (19%) faced distant failure, and 19 patients (15%) died from metastatic disease. Patients with < 90% necrosis had higher rates of loco-regional (13% vs. 0%, p = 0.207) and distant failure (25% vs. 0%, p = 0.021). Three-year LRFS was 86% for < 90% necrosis and 100% for ≥ 90% necrosis (p = 0.160). DDFS was 75% for < 90% necrosis versus 100% for ≥ 90% (p = 0.036). OS rates were 79% and 93%, respectively (p = 0.290).

Conclusion: Preoperative RT with UHYPO-RT was associated with a higher rate of tumour necrosis ≥ 90% than CONV-RT. Our data suggest that more extensive necrosis is associated with better clinical outcomes.

Background and objectives: Prostate cancer treatments paradigms are in continuous evolution, especially in metastatic setting. In this context, the Genito-Urinary (GU) Group of Italian Association of Radiotherapy and Clinical Oncology (AIRO) aimed to create a Consensus on radiotherapy indication in de novo metastatic hormone sensitive prostate cancer both on primary tumour and metastatic sites.

Methods: A panel of experts, involved in clinical management of prostate cancer, through the estimate-talk-estimate (ETE) method, developed a list of items and correspondent statements on the identified topic.

Key findings: Seven conclusive items were identified with 12 statements about the chosen topic, radiotherapy in metastatic hormone sensitive prostate cancer on primary tumour and metastatic sites.

Conclusions and clinical implications: This consensus might help clinicians in prostate cancer managing in daily clinical practice.

Purpose: The aim of our study was to evaluate survival and patterns of relapse for patients with perineural spread (PNS) of cutaneous squamous cell carcinoma (cSCC), who have undergone curative intent skull base surgery and/or radiation therapy. In addition, we modified the classification of zone 2 disease into 2a and 2b and reported the respective outcome.

Methods and materials: A review of a prospective database of patients who received diagnoses of PNS of cSCC and were treated with curative intent skull base surgery and/or radiation therapy between the years of 2013 and 2020 was conducted. Kaplan-Meier methods were used to estimate relapse-free survival (RFS), disease-specific survival (DSS), and overall survival (OS). Cox proportional hazard modeling was performed to test associations between patient factors and survival outcomes.

Results: Eighty patients with a median follow-up of 36 months were included in the study. The 5-year RFS was 61% (95% CI, 48%-71%), the DSS was 77% (95% CI, 63%-86%), and OS was 67% (95% CI, 53%-78%). In multivariable modeling, involvement of 2 or more nerves was strongly associated with worse 5-year RFS (HR, 4.0; P ≤ .001), DSS (HR, 4.5; P = .004), and OS (HR, 4.3; P = .002). Age group (≥65 years) (HR, 5.1; P = .010) and immune compromise (HR, 10.7; P = .001) were strongly associated with worse OS but not DSS or RFS. The majority of relapses (60%) occurred at the local skin sites.

Conclusions: Our study demonstrated surgery followed by radiation therapy was safe and effective in the management of cSCC with PNS. We did not detect a difference in outcome between zones 2a and 2b though further study is required. The most common mode of relapse was at the skin epidermis and/or adjacent dermis highlighting the importance of adequate local skin dose delivery.

Purpose/objectives: Difficulties and delays in insurance pre-authorization (pre-auth) can negatively impact patient care, resulting in postponing, modifying, or even cancelling radiation therapy for patients. We aimed to perform a root cause analysis for pre-auth delays in our department and implement solutions to optimize our workflow. Our primary objectives were to decrease mean time for clinical treatment plan (CTP) completion, and for number of cases delayed/denied, by 50% each.

Materials/methods: We performed a root cause analysis for pre-auth delays, and used the PDSA & A3 quality improvement methods. We sampled ∼2 cases per disease site (19 cases from July - Aug 2022) to determine the baseline. Countermeasures included: 1) optimizing our CTP templates per disease site to contain the specific clinical information required for pre-auth, 2) formalizing earlier completion of CTPs in our Care Path®, and 3) formalizing the pre auth workflow in our Care Path®. We tracked various metrics, including mean time for CTP completion, % usage of our Care Path®, % usage of revised CTP templates, mean time until pre-auth initiated & completed, and % of cases delayed/denied. Two-tailed T-tests and Chi-squared tests were used to generate p-values comparing mean values and percentages, respectively.

Results: 495 patients completed CT simulation in our department between October 2022 and February 2023. Mean time for CTP completion (Day 0 = day of CT simulation scheduling) improved from 16 days at baseline to 4 days (p<0.001). Care Path® usage improved from 16% to 97% (p<0.001), as did usage of our revised CTP templates, from 0% to 97% (p<0.001). The mean time from insurance pre-auth initiation to completion improved from 5 days to 1 day. The percent of cases that were delayed/denied was reduced significantly from 32% to 8% (p<0.001).

Conclusions: Improving timeliness and details of CTP documentation and pre-auth by using our Care Path® and optimizing CTP templates improved efficiency of insurance pre-auth completion and reduced the number of cases delayed/denied.